Therefore, the combination of increased IgM in MS, increased proportions of IgG3 and IgG1 in MS, and decreased IgG2 and IgA levels in CIS and MS suggest that dysregulation of antibody isotype diversification is occurring in people with high-risk CIS and MS. The gene discussed is CD79A; the disease is myeloid sarcoma.